Sign in
IBIO Stock Price, Chart, Stats & News
iBio, Inc.
Save
26.68M
Market cap
–
Current P/E
–
Forward P/E
IBIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -76.67% |
Operating margin | -7657.67% |
Pretax margin | -8245.67% |
Net margin | -8245.67% |
Effective tax rate | – |
ROA | -38.42% |
ROE | -71.26% |
D/E | 0.04x |
Interest coverage ratio | -131.27x |
IBIO valuation
P/E | – |
P/S | 92.63x |
P/B | 3.08x |
P/CF | -9.37x |
P/FCF | -1.45x |
P/OCF | -9.37x |
PEG | -0.25x |
EV multiple | -2.52x |
About
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis.
Similar securities
Based on sector and market capitalization
Report issue